0000950142-22-002306.txt : 20220725 0000950142-22-002306.hdr.sgml : 20220725 20220725171717 ACCESSION NUMBER: 0000950142-22-002306 CONFORMED SUBMISSION TYPE: 424B7 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220725 DATE AS OF CHANGE: 20220725 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NRX Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001719406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822844431 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B7 SEC ACT: 1933 Act SEC FILE NUMBER: 333-264201 FILM NUMBER: 221104293 BUSINESS ADDRESS: STREET 1: 1201 ORANGE STREET STREET 2: SUITE 600 CITY: WILMINGTON STATE: DE ZIP: 19801 BUSINESS PHONE: 484-254-6134 MAIL ADDRESS: STREET 1: 1201 ORANGE STREET STREET 2: SUITE 600 CITY: WILMINGTON STATE: DE ZIP: 19801 FORMER COMPANY: FORMER CONFORMED NAME: Big Rock Partners Acquisition Corp. DATE OF NAME CHANGE: 20171012 424B7 1 eh220273678_424b7-201.htm FORM 424B7

PROSPECTUS SUPPLEMENT NO. 1	Filed Pursuant to Rule 424(b)(7)
(to prospectus dated June 13, 2022)	Registration No. 333-264201

NRX Pharmaceuticals, Inc.

Prospectus Supplement No. 1 dated July 25, 2022 to the Prospectus (the “Prospectus”) dated June 13, 2022, of NRx Pharmaceuticals, Inc. (the “Company”), included in Registration Statement on Form S-3, Registration No. 333-264201 )

This prospectus supplement updates and supplements the information in the above-captioned Prospectus with respect to one of the Selling Securityholders listed in the Prospectus as described below.

The Prospectus on pages 18 and 19 under the caption “Selling Securityholders”, lists Daniel Javitt as a selling securityholder with respect to 13,102,676 shares of Company Common Stock, all of which were held through Glytech, LLC. Daniel Javitt is a co-founder of the Company and owns 100% of Glytech, LLC. Since the date of the Prospectus, Daniel Javitt has transferred (i) 445,712 of such shares in open market transaction and (ii) 2,000,000 of such shares to the Comet 2022 Charitable Remainder Unitrust. The Prospectus now covers the offer and sale as selling securityholder (i) by the Comet 2022 Charitable Remainder Unitrust, with respect to 2,000,000 of such shares and (ii) by Glytech, LLC with respect to 10,656,964 of such shares.

This Prospectus Supplement is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This Prospectus Supplement should be read in conjunction with the Prospectus and, if there is any inconsistency between the information in the Prospectus and this Prospectus Supplement, you should rely on the information in this Prospectus Supplement.

The date of this prospectus is July 25, 2022.